cigna glp-1 coverage news doubles down on support programs with 2 new launches Weight loss drugs' high costs

Nonetheless, the results provide reassuring evidence for clinicians and patients, supporting the continued use of GLP-1 receptor agonists in Type 2 diabetes without added concern for pancreatitis risk, and raising the possibility of improved outcomes in those who do develop the condition

The results showed that after 12 months of treatment, the total fat mass of the patients decreased by 18%, the decline in lean body mass stabilized after the initial appearance of treatment, and grip strength improved significantly

Common GLP-1 medications include: Liraglutide : Marketed as Saxenda and Victoza

Studies suggest GLP-1 receptor agonists may slow kidney function decline, potentially through anti-inflammatory mechanisms alongside improved glycaemic control and blood pressure reduction

The matched control group of individuals without GLP-1 RA prescriptions had a mean (SD) age of 59.3 (13.9) years and included 93 757 females (50.7%) and 91 309 males (49.3%), with 5716 individuals who identified as Asian (3.1%), 33 209 as Black or African American (17.9%), 17 693 as Hispanic (9.6%), 128 769 as not Hispanic or Latino (69.6%), and as 114 315 White (61.8%)

Bring copies of your U.S